Live Breaking News & Updates on புஜோல் மருத்துவமனை
Stay updated with breaking news from புஜோல் மருத்துவமனை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article BARCELONA, Spain, Jan. 18, 2021 /PRNewswire/ Grifols (MCE: GRF, MCE: GRF.P,NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people s health and well-being, today announced it will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex®-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease. The new drug would provide immediate post-exposure protection against the virus and would be especially useful as a complement to the vaccine in the early phase after vaccination. In addition, it could protect the elderly and healthcare workers as well as immunocompromised patients for whom vaccination isn t recommended. It could also help contain outbreaks in places where the vaccination hasn t begun ....
Can someone who has received the covid vaccine pass the virus on? ara.cat - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ara.cat Daily Mail and Mail on Sunday newspapers.
Credit: IRB Barcelona T-cell acute lymphoblastic leukaemia (T-ALL) is a cancer of the blood that affects mainly children, but also less frequently adults. In adults, although the response to treatment might be initially positive, relapses are common and have a poor prognosis. A collaborative project between IRB Barcelona s Biomedical Genomics lab, headed by ICREA researcher Núria López-Bigas, Anna Bigas group at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), and Josep Maria Ribera s lab at the Josep Carreras Leukaemia Research Institute (IJC) has discovered that the cells responsible for resistance to T-ALL treatment in adults are already present in the tumours before diagnosis. ....
Researchers discover cells responsible for resistance to T-ALL treatment T-cell acute lymphoblastic leukemia (T-ALL) is a cancer of the blood that affects mainly children, but also less frequently adults. In adults, although the response to treatment might be initially positive, relapses are common and have a poor prognosis. A collaborative project between IRB Barcelona s Biomedical Genomics lab, headed by ICREA researcher Núria López-Bigas, Anna Bigas group at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), and Josep Maria Ribera s lab at the Josep Carreras Leukaemia Research Institute (IJC) has discovered that the cells responsible for resistance to T-ALL treatment in adults are already present in the tumors before diagnosis. ....